Uterine leiomyomas

Clinical Gynecology

Volumn , Issue , 2006, Pages 179-204

  Victory, Rahi ^a,b   Romano, Walter ^c,d   Bennett, John ^d   Diamond, Michael P ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b DETROIT MEDICAL CENTER   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882459968     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06691-7.50019-4     Document Type: Chapter

References (194)

1. Schwartz SM Epidemiology of uterine leiomyomata. Clin Obstet Gynecol 2001, 44:316-326. (IV, C).
2. Buttram VC, Reiter RC Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 1981, 36:433-445. (IV, C).
3. Lumsden MA, Wallace EM Clinical presentation of uterine fibroids. Baillieres Clin Obstet Gynaecol 1998, 12:177-195. (IV, C).
4. Cramer SF, Patel A The frequency of uterine leiomyomas. Am J Clin Pathol 1990, 94:435-438. (IIb, B).
5. Marshall LM, Speigelman D, Barbieri R, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997, 90:967-973. (IIb, B).
6. Ross RK, Pike M, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ 1986, 293:359-362. (III, B).
7. Faerstein E, Szklo M, Rosenshein NB Risk factors for uterine leiomyoma: a practice-based case control study. 1. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol 2001, 153:1-10. (III, B).
8. Baird DD, Dunson DB, Hill MC, et al. high cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003, 188:100-107. (IIb, B).
9. Walker CL Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Rec Prog Horm Res 2002, 57:277-294. (IV, C).
10. Marshall LM, Spiegelman, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998, 70:432-439. (IIb, B).
11. Samadi AR, Lee NC, Flanders WD, et al. Risk factors for self reported uterine fibroids: a case control study. Am J Public Health 1996, 86:858-862. (III, B).
12. Romieu I, Walker AM, Jick S Determinants of uterine fibroids. Post Market Surveil 1991, 5:119-133. (IV, C).
13. Lumbiganon P, Rugpao S, Phandhu-Fung S, et al. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicenter case-control study. BJOG 1995, 103:909-914. (IIb, B).
14. Wise LA, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004, 159:113-123. (IIb, B).
15. Chen CR, Buck GM, Courey NG, et al. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 2001, 153:20-26. (III, B).
16. Parazzini F, Negri E, La Vecchia C, et al. Reproductive factors and risk of uterine fibroids. Epidemiology 1996, 7:440-442. (III, B).
17. Rein MS, Barbieri RL, Friedman AJ Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995, 172:14-18. (IV, C).
18. Sener AB, Seckin NC, Ozmen S, et al. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril 1996, 65:354-357. (Ib, A).
19. Yang CH, Lee JN, Hsu SC, et al. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women-a 3-year study. Maturitas 2002, 43:35-39. (III, B).
20. Fedele L, Bianchi S, Raffaelli R, et al. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reproid Biol 2000, 88:91-94. (Ib, A).
21. de Aloysio D, Altieri P, Penacchioni P, et al. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. Maturitas 1998, 29:261-264. (Ib, A).
22. Reed SD, Cushing-Haugen KL, Daling JR, et al. Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas. Menopause 2004, 11:214-222. (III, B).
23. Marshall LM, Spiegelman D, Manson JE, et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiol 1998, 9:511-517. (IIb, B).
24. Parazzini F, LaVecchia C, Negri E, et al. Epidemiologic characteristics of women with uterine fibroids: case-control study. Obstet Gynecol 1988, 72:853-857. (III, B).
25. Parazzini F, Negri E, La Vecchia C, et al. Uterine myomas and smoking: results from an Italian study. J Reprod Med 1996, 41:316-320. (III, B).
26. Flake GP, Andersen J, Dixon D Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003, 111:1037-1054. (IV, C).
27. Townsend DE, Sparkes RS, Baluda MC, et al. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 1970, 107:1168-1173. (III, B).
28. Mashal RD, Fejzo MLS, Friedman AJ, et al. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata. Genes Chromosomes Cancer 1994, 11:1-6. (IIb, B).
29. Hashimoto K, Azuma C, Kamiura S, et al. Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosone-linked phosphoglycerokinase gene. Gynecol Obstet Invest 1995, 40:204-208. (IIb, B).
30. Gross KL, Morton CC Genetics and the development of fibroids. Clin Obstet Gynecol 2001, 44:335-349. (IV, C).
31. Gattas GJ, Quade BJ, Nowak RA, et al. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer 1999, 25:316-322. (IIb, B).
32. Pedeutour F, Quade BJ, Weremowicz S, et al. Localization and expression of the human estrogen receptor beta gene in uterine leiomyomata. Genes Chromosomes Cancer 1998, 23:361-366. (IIb, B).
33. Kazmierczak B, Dal Cin P, Wanschura S, et al. HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Genes Chromosomes Cancer 1998, 23:279-285. (IIb, B).
34. Tallini G, Dal Cin P, Rhoden KJ, et al. Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. Am J Pathol 1997, 151:37-43. (III, B).
35. Xiao S, Lux M, Reeves R, et al. HMGI(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma. Am J Pathol 1997, 150:901-910. (Comment).
36. Dal Cin P, Wanschura S, Christiaens MR, et al. Hamartoma of the breast with involvement of 6p21 and rearrangement of HMGIY. Genes Chromosomes Cancer 1997, 20:90-92. (III, B).
37. Dal Cin P, Van Den Berghe H, et al. Involvement of 6p in an endometrial polyp. Cancer Genet Cytogenet 1991, 51:279-280. (III, B).
38. Somberger KS, Weremovicz S, Williams AJ, et al. Expression of HMGIY in three uterine leiomyomata with complex rearrrangements of chromosome 6. Cancer Genet Cytogenet 1999, 114:9-16. (III, B).
39. Ligon AH, Morton CC Genetics of uterine leiomyomata. Genes Chromosomes Cancer 2000, 28:235-245. (III, B).
40. Vanni R, Van Roy N, Lecca U, et al. Uterine leiomyoma cytogenetics. 3. Interphase cytogenetic analysis of karyotypically normal uterine leiomyoma excludes possibility of undetected trisomy 12. Cancer Genet Cytogenet 1992, 62:40-42. (III, B).
41. Ligon AH, Morton CC Leiomyomata: heritability and cytogenetic studies. Genes Chromosomes Cancer 2000, 28:235-245. (IV, C).
42. Treloar SA, Martin NG, Dennerstein L, et al. Pathways to hysterectomy: insights from longitudinal twin research. Am J Obstet Gynecol 1992, 167:82-88. (IIb, B).
43. Luoto R, Kaprio J, Rutanen EM, et al. Heritability and risk factors of uterine fibroids-the Finnish Twin Cohort study. Maturitas 2000, 37:15-26. (IIb, B).
44. Winkler VDH, Hoffmann W Regarding the question of inheritance of uterine myoma. Deutsche-Medizinische Wochenschrift 1938, 68:235-257. (IV, C).
45. Kurbanova M, Koroleva AG, Sergeev AS Genetic-epidemiological analysis of uterine myoma: estimate of risk to relatives. Genetika 1989, 25:1896-1898. (IV, C).
46. Vikhlyaeva EM, Khodzhaeva ZS, Fantschenko ND Familial predisposition to uterine leiomyomas. Int J Gynecol Obstet 1995, 51:127-131. (IIb, B).
47. Schwartz SM, Voigt L, Tickman E, et al. Familial aggregation of uterine leiomyomata. Am J Epidemiol 2000, 151:S10. (III, B).
48. Rein MS, Barbieri RL, Friedman AJ Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995, 172:14-18. (IV, C).
49. Sadan O, van Iddekinge B, van Gelderen CJ, et al. Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium. Ann Clin Biochem 1987, 24:263-267. (III, B).
50. Benassayag C, Leroy MJ, Rigourd V, et al. Estrogen receptors (ERalpha/ERbeta) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol 1999, 276:E1112-E1118. (III, B).
51. Folkerd EJ, Newton CJ, Davidson K, et al. Aromatase activity in uterine leiomyomata. J Steroid Biochem 1984, 20:1195-1200. (IIb, B).
52. Sumitani H, Shozu M, Segawa T, et al. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinol 2000, 141:3852-3861. (IIb, B).
53. Yamamoto T, Takamori K, Okada H Estrogen biosynthesis in leiomyoma and myometrium of the uterus. Horm Metab Res 1984, 16:678-679. (III, B).
54. Spellacy WN, Le Maire WJ, Buhi WC, et al. Plasma growth hormone and estradiol levels in women with uterine myomas. Obstet Gynecol 1972, 40:829-834. (III, B).
55. Maheux R, Lemay-Turcot L, Lemay A Daily follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone in ten women harboring uterine leiomyomas. Fertil Steril 1986, 46:205-208. (IIb, B).
56. Dawood MY, Khan-Dawood FS Plasma insulin-like growth factor-1, CA-125, estrogen, and progesterone in women with leiomyomas. Fertil Steril 1994, 61:617-621. (IIa, B).
57. Liehr JG, Ricci MJ, Jefcoate CR, et al. 4-hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci USA 1995, 92:9220-9224. (III, B).
58. Brandon DD, Bethea CL, Strawn EY, et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993, 169:78-85. (III, B).
59. Viville B, Charnock-Jones DS, Sharkey AM, et al. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod 1997, 12:815-822. (III, B).
60. Otubu JA, Buttram VC, Besche NF, et al. Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol 1982, 143:130-133. (III, B).
61. Tiltman AJ The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 1985, 4:89-96. (III, B).
62. Kawaguchi D, Fujii S, Konishi I, et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989, 160:637-641. (III, B).
63. Kawaguchi K, Fujii S, Konishi I, et al. Ultrastructural study of cultured smooth muscle cells from uterine leiomyoma and myometrium under the influence of sex steroids. Gynecol Oncol 1985, 21:32-41. (III, B).
64. Maruo T, Matsuo H, Samoto T, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000, 65:585-592. (III, B).
65. Hofmann GE, Rao CV, Barrows GH, et al. Binding sites for epidermal growth factor in human uterine tissues and leiomyoma. J Clin Endocrinol Metab 1984, 58:880-884. (III, B).
66. Nelson KG, Takahashi T, Bossert NL, et al. Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc Natl Acad Sci USA 1991, 88:21-25. (III, B).
67. Yeh J, Rein M, Nowak R Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometrial and leiomyoma. Fertil Steril 1991, 56:997-1000. (III, B).
68. Rossi MJ, Chegini N, Masterson BJ Presence of epidermal growth factor, platelet-derived growth factor (PDGF), and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinol 1992, 130:1716-1727. (III, B).
69. Lyons RM, Moses HL Transforming growth factors and the regulation of cell proliferation. Eur J Biochem 1990, 187:467-473. (IV, C).
70. Matsuo H, Maruo T, Samoto T Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 1997, 82:293-299. (III, B).
71. Valenti MT, Azzarello G, Vinante O, et al. Differentiation, proliferation and apoptosis levels in human leiomyoma and leiomyosarcoma. J Cancer Res Clin Oncol 1998, 124:93-105. (III, B).
72. Vu K, Greenspan DL, Wu T-C, et al. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas. Hum Pathol 1998, 29:359-363. (III, B).
73. Lumsden MA, Wallace EM Clinical presentation of uterine fibroids. Baillieres Clin Obstet Gynecol 1998, 12:177-195. (IV, C).
74. Stewart EA Uterine fibroids. Lancet 2001, 357:293-298. (IV, C).
75. Stovall DW Clinical symptomatology of uterine leiomyomas. Clin Obstet Gynecol 2001, 44:364-371. (IIb, B).
76. Bettocchi S, Ceci O, Vicino M, et al. Diagnostic inadequacy of dilation and curettage. Fertil Steril 2001, 75:803-805. (III, B).
77. Pron G, Bennett J, Common A, et al. The Ontario Uterine Fibroid Embolization Trial. 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril 2003, 79:120-127. (IIb, B).
78. Rybo G, Leman J, Tibbin R Epidemiology of Menstrual Blood Loss: Mechanisms of Menstrual Bleeding 1985, 181-193. Raven Press, New York, (III, B).
79. Farrer-Brown G, Bobbeilby JOW, Tarbit NH Venous changes in the endometrium of myomatous uteri. Obstet Gynecol 1971, 38:743-751. (III, B).
80. Yamaguchi M, Mori N Prostaglandin production by human myometrium, uterine cervix and leiomyoma. Prostaglandins Leukot Med 1987, 29:107-112. (III, B).
81. Anderson J Factors in fibroid growth. Baillieres Clin Obstet Gynecol 1998, 12:233-238. (IV, C).
82. Vercellini P, Vendola N, Ragni G, et al. Abnormal uterine bleeding associated with iron deficiency anemia: etiology and role of hysteroscopy. J Reprod Med 1993, 38:502-504. (IV, C).
83. Lippman SA, Warner M, Samuels S, et al. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril 2003, 80:1488-1494. (IIb, B).
84. Kjerulff KH, Langenberg P, Seidman JD, et al. uterine leiomyomas: racial differences in severity, symptoms, and age at diagnosis. J Reprod Med 1994, 41:483-490. (IIb, B).
85. Hara T, Tsuchida M, Takai K, et al. Ureteral obstruction in a transplanted kidney secondary to a subserous myoma uteri. Transplant 2003, 75:1915-1916. (III, B).
86. Reiter RC, Wagner PL, Gambone JC Routine hysterectomy for large asymptomatic uterine leiomyomata: a reappraisal. Obstet Gynecol 1992, 79:481-484. (III, B).
87. Chaparala RPC, Fawole AS, Ambrose NS, et al. Large bowel obstruction due to a benign uterine leiomyoma. Gut 2004, 53:386. (III, B).
88. Bajekal N, Li TC Fibroids, infertility and pregnancy wastage. Hum Reprod Update 2000, 6:614-620. (IV, C).
89. Pritts EA Fibroids and infertility: a systematic review of the evidence. Obstet Gynecol Surv 2001, 56:483-491. (IV, C).
90. Ubaldi F, Tournaye H, Camus M, et al. Fetility after hysteroscopic myomectomy. Hum Reprod Update 1995, 1:81-90. (IV, C).
91. Bulletti C, De Ziegler D, Polli V, et al. The role of leiomyomas in infertility. J Am Assoc Gynecol Laparosc 1999, 6:441-445. (III, B).
92. Donnez J, Jadoul P What are the implications of myomas on fertility? A need for a debate?. Hum Reprod 2002, 17:1424-1430. (IV, C).
93. Hart R, Khalaf Y, Yeong CT, et al. A prospective controlled study of the effect of intramural uterine fibroids on the outcome of assisted conception. Hum Reprod 2001, 16:2411-2417. (IIa, B).
94. Oliveira FG, Abdelmassih VG, Diamond MP, et al. Impact of sub-serosal and intramural uterine fibroids that do not distort the endometrial cavity on the outcome of in vitro fertilization-intracytoplasmic sperm injection. Fertil Steril 2004, 81:582-587. (IIa, B).
95. Check JH, Choe JK, Lee G, et al. The effect on IVF outcome of small intramural fibroids not compressing the uterine cavity as determined by a prospective matched control study. Hum Reprod 2002, 17:1244-1248. (IIa, B).
96. Ng EHY, Ho PC Doppler ultrasound examination of uterine arteries on the day of oocyte retrieval in patients with uterine fibroids undergoing IVF. Hum Reprod 2002, 17:765-770. (IIb, B).
97. Surrey ES Impact of intramural leiomyomata on in-vitro fertilization-embryo transfer cycle outcome. Curr Opin Obstet Gynecol 2003, 15:239-242. (IV, C).
98. Muram D, Gillieson M, Walters JH Myomas of the uterus in pregnancy: ultrasonographic follow-up. Am J Obstet Gynecol 1980, 138:16-19. (IV, C).
99. Myers ER, Barber M, Couchman GM, et al. Management of uterine fibroids. Evidence Report/Technology Assessment 2001, Agency for Health Care Research and Quality, Rockville, Md, Available at Accessed http://www.ahcpr.gov/clinic/epcix.htm4/15/05. (IV, C).
100. Benson CB, Chow JS, Chang-Lee W, et al. Outcome of pregnancies in women with uterine leiomyomas identified by sonography in the first trimester. J Clin Ultrasound 2001, 29:261-264. (III, B).
101. Li TC, Mortimer R, Cooke ID Myomectomy: a retrospective study to examine reproductive performance before and after surgery. Hum Reprod 1999, 14:1735-1740. (III, B).
102. Coronado GD, Marshall LM, Schwartz SM Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population-based study. Obstet Gynecol 2000, 95:764-769. (III, B).
103. Salvador E, Bienstock J, Blakemore KJ, et al. Leiomyomata uteri, genetic amniocentesis, and the risk of second-trimester spontaneous abortion. Am J Obstet Gynecol 2002, 186:913-915. (IIa, B).
104. Lanouette JM, Diamond MP Pregnancy in women with myoma uteri. Infert Reprod Med Clin North Am 1996, 7:19-32. (IV, C).
105. Katz V, Dotters DJ, Droegemueller W Complications of uterine leiomyomas in pregnancy. Obstet Gynecol 1989, 73:593-596. (III, B).
106. Cantuaria GHC, Angioli R, Frost L, et al. Comparison of bimanual examination with ultrasound examination before hysterectomy for uterine leiomyoma. Obstet Gynecol 1998, 92:109-112. (III, B).
107. Goldberg JM, Falcone T, Attaran M Sonohysterographic evaluation of uterine abnormalities noted on hysterosalpingography. Hum Reprod 1997, 12:2151-2153. (III, B).
108. Pittaway DE, Winfield AC, Maxson W, et al. Prevention of acute pelvic inflammatory disease after hysterosalpingography: efficacy of doxycycline prophylaxis. Am J Obstet Gynecol 1983, 147:623-626. (III, B).
109. Hurley V Imaging techniques for fibroid detection. Baillieres Clin Obstet Gynecol 1998, 12:213-224. (IV, C).
110. Karasick S, Lev-Toaff AS, Toaff ME Imaging of uterine leiomyomas. Am J Roentgenol 1992, 158:799-805. (IV, C).
111. Mayer DP, Shipilov V Ultrasonography and magnetic resonance imaging of uterine fibroids. Obstet Gynecol Clin North Am 1995, 22:667-725. (IV, C).
112. Fedele L, Bianchi S, Dorta M, et al. Transvaginal sonography versus hysteroscopy in the diagnosis of uterine submucous myomas. Obstet Gynecol 1991, 77:745-748. (III, B).
113. Dueholm M, Lundorf E, Hansen ES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2002, 186:409-415. (IIb, B).
114. de Vries LD, Dijkhuizen FP, Mol BW, et al. Comparison of transvaginal sonography, saline infusion sonography, and hysteroscopy in premenopausal women with abnormal uterine bleeding. J Clin Ultrasound 2000, 28:217-223. (IIb, B).
115. Sylvestre C, Child TJ, Tulandi T, et al. A prospective study to evaluate the efficacy of two- and three-dimensional sonohysterography in women with intrauterine lesions. Fertil Steril 2003, 79:1222-1225. (IIb, B).
116. Brunner M, Obruca A, Bauer P, et al. Clinical application of volume estimation based on three dimensional ultrasonography. Ultrasound Obstet Gynecol 1995, 6:359-361. (III, B).
117. Jurkovic D Three-dimensional ultrasound in gynecology: a critical evaluation. Ultrasound Obstet Gynecol 2002, 19:109-117. (IV, C).
118. Pretorius DH, Becker E, Lev-Toaff AS Impact of sonohysterography on the management of women with uterine myomas. Ultrasound Obstet Gynecol 2001, 18(Suppl):2. (IV, C).
119. de Vries LD, Paul HLF, Dijkhuizen J, et al. Comparison of transvaginal sonography, saline infusion sonography, and hysteroscopy in premenopausal women with abnormal uterine bleeding. J Clin Ultrasound 2000, 28:217-223. (IIb, B).
120. Hricak H, Tscholakoff D, Heinrichs L, et al. Uterine leiomyomas: correlation of MR, histopathological findings, and symptoms. Radiology 1986, 158:385-391. (III, B).
121. Ascher SM, Jha RC, Reinhold C Benign myometrial conditions: leiomyomas and adenomyosis. Top Magn Reson Imaging 2003, 14:281-304. (IV, C).
122. Lefebvre G, Vilos GA, Allaire C, et al. SOGC Clinical practice guidelines: the management of uterine leiomyomas. J Obstet Gynaecol Can 2003, 25:396-405. (III, B).
123. Schwartz LB, Diamond MP, Schwartz PE Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol 1993, 168:180-183. (III, B).
124. Meyer WR, Mayer AR, Diamond MP, et al. Unsuspected leiomyosarcoma: treatment with a gonadotropin-releasing hormone analogue. Obstet Gynecol 1990, 75:529-532. (III, B).
125. Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993, 76:1217-1223. (Ib, A).
126. Sivin I, Stern J Health during prolonged use of levonorgestrel 20 mcg/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research. Fertil Steril 1994, 61:70-77. (Ib, A).
127. Pekonen F, Nyman T, Lahteenmaki P, et al. Intrauterine progestin induces continuous insulin-like growth factor-binding protein-1 production in the human endometrium. J Clin Endocrinol Metab 1992, 75:660-664. (IIb, B).
128. Makarainen L, Ylikorkala O Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. BJOG 1986, 93:974-978. (Ib, A).
129. Ylikorkala O, Pekonen F Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol 1986, 68:10-12. (IIa, B).
130. Friedman AJ, Barbieri RL, Benacerraf BR, et al. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil Steril 1987, 48:560-564. (Ib, A).
131. Friedman AJ, Hoffman DI, Comite F, et al. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. Obstet Gynecol 1991, 77:720-725. (Ib, A).
132. Chavez NF, Stewart EA Medical treatment of uterine fibroids. Clin Obstet Gynecol 2001, 44:372-384. (IV, C).
133. Shaw RW Gonadotropin hormone-releasing hormone analogue treatment of fibroids. Baillieres Clin Obstet Gynecol 1998, 12:245-268. (IV, C).
134. Lemay A, Maheux R GnRH agonists in the management of uterine leiomyoma. Infert Reprod Med Clin North Am 1996, 7:33-55. (IV, C).
135. Farquahar C, Arroll B, Ekeroma A, et al. An evidence based guideline for the management of uterine fibroids. Aust N Z J Obstet Gynaecol 2001, 41:125-140. (IV, C).
136. Donnez J, Schrurs B, Gillerot S, et al. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril 1989, 51:947-950. (III, B).
137. Watanabe Y, Nakamura G Effects of two different doses of leuprolide acetate depot on uterine cavity area in patients with uterine leiomyomata. Fertil Steril 1995, 63:487-490. (Ib, A).
138. Friedman AJ, Daly M, Juneau-Norcross MJ, et al. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Fertil Steril 1992, 8:413-415. (III, B).
139. Gutmann JN, Thornton KL, Diamond MP, et al. Evaluation of leuprolide acetate treatment on histopathology of uterine myomata. Fertil 1994, 61:626-662. (III, B).
140. Lethaby A, Vollenhoven B, Sowter M Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG 2002, 109:1097-1108. (IV, C).
141. Dubuisson JB, Fauconnier A, Fourchotte V, et al. Laparoscopic myomectomy: predicting the risk of conversion to an open procedure. Human Reprod 2001, 16:1726-1731. (IIb, B).
142. Friedman AJ, Harrison-Atlas D, Barbieri RL, et al. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril 1989, 51:251-256. (Ib, A).
143. Matta WHM, Stabile I, Shaw RW, et al. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin releasing hormone agonist buserelin. Fertil Steril 1988, 46:1083-1085. (III, B).
144. Shaw RW Blood flow changes in the uterus induced by treatment with GnRH analogues. Hum Reprod 1996, 11:27-32. (IV, C).
145. Serra GB, Panetta V, Colosimo M, et al. Efficacy of leuprorelin acetate depot in symptomatic fibromatous uteri: the Italian multicenter trial. Clin Ther 1992, 14:57-73. (IIb, B).
146. West CP, Lumsden MA, Baird JT Goserelin in the treatment of fibroids. BJOG 1992, 99(Suppl):27-30. (IV, C).
147. Cirkel U, Ochs H, Scheiner HPG, et al. Experience with leuprolin acetate depot in the treatment of fibroids: a German multicenter study. Clin Ther 1992, 14(Suppl A):37-50. (IIb, B).
148. Lumsden MA, West CP, Thomas E, et al. Treatment with the gonadotropin-releasing hormone agonist goserelin before hysterectomy for uterine fibroids. BJOG 1994, 101:438. (Ib, A).
149. Friedman AJ, Daly M, Juneau-Norcross M, et al. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 1993, 76:1439-1445. (Ib, A).
150. Friedman AJ Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study. Fertil Steril 1989, 51:526-528. (III, B).
151. Murphy AA RU 486 in the treatment of leiomyomata uteri. Infert Reprod Med Clin North Am 1996, 7:57-68. (IV, C).
152. DeManno D, Elger W, Garg R, et al. Asoprisnol (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003, 68:1019-1032. (IV, C).
153. Chwalisz K, Lamar Parker R, Williamson S, et al. Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM) J867. J Soc Gynecol Invest 2003, 10. [abstract 636].
154. Ueki M, Okamato Y, Tsurunaga T, et al. Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin. J Obstet Gynecol 1995, 21:1-7. (IIa, B).
155. De Leo V, Morgante G, Lanzetta D, et al. Danazol administration after gonadotropin-releasing hormone analogue reduces rebound of uterine myomas. Hum Reprod 1997, 12:357-360. (III, B).
156. Takebayashi T, Fujino Y, Umesaki N, et al. Danazol suspension injected into the uterine cervix of patients with adenomyomas and myoma. Gynecol Obstet Invest 1995, 39:207-211. (III, B).
157. Coutinho EM, Goncalves MT Long-term treatment of leiomyomas with gestrinone. Fertil Steril 1989, 51:939-946. (Ib, A).
158. Mitwally MF, Casper RF Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001, 75:305-309. (IIb, B).
159. Shozu M, Murakami K, Segawa T, et al. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil Steril 2003, 79:628-631. (III, B).
160. Eldar-Geva T, Healy DL Other medical management of uterine fibroids. Baillieres Clin Obstet Gynaecol 1998, 12:269-288. (IV, C).
161. Jirecek S, Lee A, Pavo I, et al. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 2004, 81:132-136. (Ib, A).
162. Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. Arterial occlusion to treat uterine myomata. Lancet 1995, 346:671-672. (IIb, B).
163. Nickolic B, Spies JB, Lundsten MJ, et al. Patient radiation dose associated with uterine artery embolization. Radiology 2002, 214:121-125. (IIb, B).
164. Walker WJ, Pelage JP, Sutton C Fibroid embolization. Clin Radiol 2002, 57:325-331. (IV, C).
165. Goldberg J, Pereira L, Berghella V Pregnancy after uterine artery embolization. Obstet Gynecol 2002, 100:869-872. (IV, C).
166. Chen YJ, Wang PH, Yuan CC, et al. Pregnancy following treatment of symptomatic myomas with laparoscopic bipolar coagulation of uterine vessels. Hum Reprod 2003, 18:1077-1081. (IIb, B).
167. Vashisht A, Studd J, Carey A, et al. Fatal septicaemia after fibroid embolization. Lancet 1999, 354:307-308. (III, B).
168. Pelage JP, Le Dref O, Soyer P, et al. Fibroid-related menorrhagia: treatment with superselective embolization of the uterine arteries and mid term follow-up. Radiology 2000, 215:428-431. (IIb, B).
169. Chrisman HB, Saker MB, Ryu R, et al. The impact of uterine fibroid embolization on resumption of menses and ovarian function. J Vasc Interv Radiol 2000, 11:699-703. (IIb, B).
170. Marret H, Alonso AM, Cottier JP, et al. Leiomyoma recurrence after uterine artery embolization. J Vasc Interv Radiol 2003, 14:1395-1399. (IIb, B).
171. Al-Fozan H, Tulandi T Factors affecting early surgical intervention after uterine artery embolization. Obstet Gynecol Surv 2002, 57:810-815. (IV, C).
172. Heinig J, Neff A, Cirkel U, et al. Recurrent leiomyomatosis peritonealis disseminata after hysterectomy and bilateral salpingo-oophorectomy during combined hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 2003, 111:216-218. (III, B).
173. Carlson KJ, Miller BA, Fowler FJ The Maine Women's Health Study: 1. Outcomes of hysterectomy. Obstet Gynecol 1994, 83:556-565. (IIb, B).
174. Dwyer N, Hutton J, Stirrat GM Randomised controlled trial comparing endometrial resection with abdominal hysterectomy for the surgical treatment of menorrhagia. BJOG 1993, 100:237-243. (Ib, A).
175. Manyonda I, Sinthamoneya E, Belli AM Controversies and challenges in the modern management of uterine fibroids. BJOG 2004, 111:95-102. (IV, C).
176. Pinto I, Chimeno P, Romo A, et al. Uterine fibroids: uterine artery embolization versus abdominal hysterectomy for treatment-a prospective, randomized, and controlled clinical trial. Radiol 2003, 226:425-431. (Ib, A).
177. Hwang JL, Seow KM, Tsai YL, et al. Comparative study of vaginal, laparoscopically assisted vaginal and abdominal hysterectomies for uterine myoma larger than 6 cm in diameter or uterus weighing at least 450 g: a prospective randomized study. Acta Obstet Gynecol Scand 2002, 81:1132-1138. (Ib, A).
178. Ribeiro SC, Ribeiro RM, Santos NC, et al. A randomized study of total abdominal, vaginal and laparoscopic hysterectomy. Int J Gynecol Obstet 2003, 83:37-43. (Ib, A).
179. Learman LA, Summitt RL, Varner RE, et al. A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol 2003, 102:453-462. (Ib, A).
180. Vollenhoven BJ, Lawrence AS, Healy DL Uterine fibroids: a clinical review. BJOG 1990, 97:285-298. (IV, C).
181. Wallach EE Myomectomy. TeLinde's Operative Gynecology 1992, 647. JB Lippincott, Philadelphia, (IV, C). 7th ed. J.D. Thompson, J.A. Rock (Eds.).
182. LaMorte AL, Lalwani S, Diamond MP Morbidity associated with abdominal myomectomy. Obstet Gynecol 1993, 82:897. (III, B).
183. Campo S, Campo V, Gambadauro P Reproductive outcome before and after laparoscopic or abdominal myomectomy for subserous or intramural myomas. Eur J Obstet Gynecol Reprod Biol 2003, 110:215-219. (IIa, B).
184. Iverson RE, Chelmow D, Strohbehn K, et al. Relative morbidity of abdominal hysterectomy and myomectomy for management of uterine leiomyomas. Obstet Gynecol 1996, 88:415-419. (III, B).
185. Rossetti A, Sizzi O, Soronna L, et al. Long-term results of laparoscopic myomectomy: recurrence rate in comparison with abdominal myomectomy. Hum Reprod 2001, 16:770-774. (Ib, A).
186. Fauconnier A, Chapron C, Babaki-Fard, et al. Recurrence of leiomyomata after myomectomy. Hum Reprod Update 2000, 6:595-602. (IV, C).
187. Stewart EA, Faur EA, Wise LA, et al. Predictors of subsequent surgery for uterine leiomyomata after abdominal myomectomy. Obstet Gynecol 2002, 99:426-432. (IIb, B).
188. Nisolle M, Smets M, Gillerot S, et al. Laparoscopic myolysis with the Nd:YAg laser. J Gynecol Surg 1993, 9:95-99. (III, B).
189. Phillips DR, Nathonson HG, Milim SJ, et al. Experience with laparoscopic leiomyoma coagulation and concomitant operative hysteroscopy. J Am Assoc Gynecol Laparosc 1997, 4:425-433. (IIb, B).
190. Vilos G, Daly L, Tse B Pregnancy outcome after laparoscopic myolysis. J Am Assoc Gynecol Laparosc 1998, 5:289-292. (III, B).
191. Glasser MH, Zimmerman JD The hydrothermablator system for management of menorrhagia in women with submucous myomas: 12- to 20-month follow-up. J Am Assoc Gynecol Laparosc 2003, 10:521-527. (IIb, B).
192. Surgical alternatives to hysterectomy in the management of leiomyomas. ACOG practice Bulletin No. 16. Int J Gynaecol Obstet 2001, 73:285-294. (IV, C).
193. Manyonda I, Sinthamoney E, Belli AM Controversies and challenges in the modern management of uterine fibroids. BJOG 2004, 111:95-102. (IV, C).
194. Myers ER, Barber MD, Gustilo-Ashby T, et al. Management of uterine leiomyomata: what do we really know?. Obstet Gynecol 2002, 100:8-17. (IV, C).